Fennec Pharmaceuticals (Fennec Pharmaceuticals) FCF Margin % : 153.87% (As of Mar. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Fennec Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Fennec Pharmaceuticals's Free Cash Flow for the three months ended in Mar. 2024 was $39.05 Mil. Fennec Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was $25.38 Mil. Therefore, Fennec Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2024 was 153.87%.

As of today, Fennec Pharmaceuticals's current FCF Yield % is 15.19%.

The historical rank and industry rank for Fennec Pharmaceuticals's FCF Margin % or its related term are showing as below:

FENC' s FCF Margin % Range Over the Past 10 Years
Min: -9163.3 Med: -1176.59 Max: 61.13
Current: 61.13

During the past 13 years, the highest FCF Margin % of Fennec Pharmaceuticals was 61.13%. The lowest was -9163.30%. And the median was -1176.59%.

FENC's FCF Margin % is ranked better than
97.42% of 1045 companies
in the Biotechnology industry
Industry Median: -139.31 vs FENC: 61.13

Fennec Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Fennec Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals FCF Margin % Chart

Fennec Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-9,173.53

-1,176.42

-80.67

Fennec Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-332.56	-118.68	-42.36	-49.92	153.87

Competitive Comparison of Fennec Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Fennec Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fennec Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's FCF Margin % falls into.

Fennec Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Fennec Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-17.143	/	21.252
	=	-80.67 %

Fennec Pharmaceuticals's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	39.047	/	25.377
	=	153.87 %

Fennec Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Fennec Pharmaceuticals (Fennec Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (NAS:FENC) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

RV41:Germany FRX:Canada

Address

68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709

Website

https://www.fennecpharma.com

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Executives

Robert Andrade	officer: Chief Financial Officer	C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703
Rosty Raykov	director, officer: Chief Executive Officer	C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703
Chris A Rallis	director	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Adrian Haigh	director	83 ANGLESSA ROAD, BALLSBRIDGE, DUBLIN L2 D04H27
Marco Maria Brughera	director	VIALE STEFINI 14, MILANO L6 00000
Khalid Islam	director	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Shubh Goel	officer: Chief Commercial Officer	1100 MAXWELL, #522, HOBOKEN NJ 07030
Southpoint Capital Advisors Lp	10 percent owner	1114 AVENUE OF THE AMERICAS, 22ND FLOOR, NEW YORK NY 10036
Spa Essetifin	10 percent owner	VIA SUDAFRICA 20, ROME L6 00144
Jodi A Cook	director	PO BOX 816, NEWTOWN PA 08540
Manchester Management Pr, Llc	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02114
Francesca Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Paolo Cavazza	10 percent owner	VIA TESSERETE, 10, LUGANO V8 V8
Silvia Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Enrico Cavazza	10 percent owner	VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040